[{"id":"b6de17b5-794f-440f-a5e5-f1a349e84075","acronym":"RUE-DDGP","url":"https://clinicaltrials.gov/study/NCT04999878","created_at":"2021-08-11T14:55:25.152Z","updated_at":"2024-07-02T16:36:26.648Z","phase":"Phase 4","brief_title":"A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.","source_id_and_acronym":"NCT04999878 - RUE-DDGP","lead_sponsor":"Zhengzhou University","biomarkers":" IL2 • CD27 • XIAP • PRF1 • UNC13D • ISG20 • RAB27A • STXBP2","pipe":"","alterations":" ","tags":["IL2 • CD27 • XIAP • PRF1 • UNC13D • ISG20 • RAB27A • STXBP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Jakafi (ruxolitinib) • etoposide IV • dexamethasone • Oncaspar liquid (pegaspargase)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/30/2021","start_date":" 05/30/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2021-08-11"}]